Zurück geht es hier Grüezi! Sie wurden auf finanzen.ch, unser Portal für Schweizer Anleger, weitergeleitet.  Zurück geht es hier.

Siegfried Aktie 142932682 / CH1429326825

21.08.2025 06:30:05

Siegfried on track to deliver profitable growth

Siegfried AG / Key word(s): Half Year Results
Siegfried on track to deliver profitable growth

21-Aug-2025 / 06:30 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 LR
The issuer is solely responsible for the content of this announcement.


Media Release
Zofingen, August 21, 2025

Ad hoc announcement pursuant to Art. 53 Listing Rules

In the first half of 2025, Siegfried (SIX: SFZN) successfully executed its strategy and continued to grow profitably. As expected, the seasonality between the half years is stronger in 2025 compared to previous years. Performance was supported by strong demand for development and manufacturing services for both drug substances and drug products across multiple markets. Profitability further increased, despite inflationary pressures in the U.S. and Germany, the final wave of customer de-stocking, and adverse currency developments. Over CHF 35 million of cash was released as a result of ongoing networking capital optimization, despite a significant increase in inventories for ongoing manufacturing that will convert into revenues in the second half of the year. Execution of the EVOLVE+ strategy remains firmly on track, sharpening Siegfried’s focus on Commercial, Development, and Operational excellence, while laying the foundation for future value creation through targeted M&A.

Marcel Imwinkelried, Chief Executive Officer: "In the first half of the year, Siegfried delivered according to plan, laying a solid foundation which allows us to confirm our 2025 outlook. This reflects the strength of our diversified customer base and our efficient operations. The execution of our strategy EVOLVE+ is making rapid progress, setting the course to outpace market growth across the key segments we are operating in and further strengthening our position as a leading CDMO in the pharmaceutical industry."

Net sales amounted to CHF 619.5 million, an increase of 1.6% in local currencies (-0.1% in Swiss Francs). The Drug Substances cluster contributed CHF 413.8 million, an increase of 2.1% in local currencies (0.6% in CHF), while Drug Products generated CHF 205.8 million in net sales, an increase of 0.7% in local currencies (-1.5% in CHF).

Core EBITDA amounted to CHF 133.9 million (prior period: CHF 132.1 million), resulting in an increased Core EBITDA margin of 21.6% (prior period: 21.3%). Core net profit amounted to CHF 65.7 million (prior period: CHF 71.7 million). This decrease is caused by negative exchange rate differences which reflect a point-in-time view. Cash flow from operating activities increased to CHF 149.6 million (prior period: CHF 118.9 million).

Strategic expansions focusing on growth opportunities
In line with the EVOLVE+ strategy, Siegfried made targeted technology investments in the first half of 2025 to capture future growth opportunities. At its ophthalmic drug manufacturing site in El Masnou, Siegfried is increasing production capacity for sterile eye drops in response to strong customer demand, with new capacity expected to be available in 2027. This expansion complements the ongoing investment in sterile eye care ointment capacity, which is expected to come online in 2026. At its Barberà del Vallès site, Siegfried is building up spray drying capacity, with first revenues anticipated in 2027. At its Hameln site, in addition to expanding its fill-finish capabilities, Siegfried is adding two new manufacturing lines for pre-filled syringes and cartridges, the first expected to start generating revenue in 2026 and the second in 2027. DINAMIQS’ new 2,500 m² cGMP viral vector manufacturing facility is on track to become operational by the end of 2025, and the construction of the new large-scale multi-purpose production plant for Drug Substances in Minden is nearing completion, with first revenues expected in the second half of 2025.

Outlook confirmed
For 2025, Siegfried expects a sales growth in the mid-single-digit percentage range in local currencies and a core EBITDA margin above 22%. Positive mid-term outlook confirmed: Continued profitable growth above market (excl. M&A).

Half-Year Results 2025

  • Net sales of CHF 619.5 million (prior year CHF 619.9 million), an increase of 1.6% in local currencies (-0.1% in CHF) 
  • Core EBITDA of CHF 133.9 million (prior year CHF 132.1 million) at a margin of 21.6% (prior year 21.3%) 
  • Core net profit of CHF 65.7 million (prior year CHF 71.7 million) 
  • Substantial progress made in net working capital optimization 
  • Outlook: Confirmed 
Contact  
   
Financial analysts: Media:
Dr. Reto Suter Peter Stierli
Chief Financial Officer Head Corporate Communications
reto.suter@siegfried.ch peter.stierli@siegfried.ch
Tel. +41 62 746 11 35 Tel. +41 62 746 15 51
   
Siegfried Holding AG  
Untere Bruehlstrasse 4  
CH-4800 Zofingen  

About Siegfried

The Siegfried Group is a global life sciences company with sites in Switzerland, Germany, Spain, France, Malta, the USA and China. In 2024, the company achieved sales of CHF 1.295 billion and employed on 31.12.2024 more than 3,800 people at thirteen sites on three continents. Siegfried Holding AG is publicly listed on SIX Swiss Exchange (SIX: SFZN). 

Siegfried is active in manufacturing pharmaceutical APIs (and their intermediates) as well as drug products (tablets, capsules, sterile vials, ampoules, cartridges and ointments) for the pharmaceutical industry and provides development services.

Cautionary statements regarding forward-looking statements


This media release includes statements concerning the future. They are based on assumptions and expectations that may prove to be wrong. They should be considered with due caution as, by definition, they contain known and unknown risks, insecurities and other factors which could result in a difference in the actual results, financial situation, developments or the success of Siegfried Holding AG or Siegfried Group from the explicit or implicit assumptions made in these statements.

expect more
 

Siegfried AG
Untere Brühlstrasse 4
4800 Zofingen, Switzerland

+41 62 746 11 11

info@siegfried.ch
www.siegfried.ch



End of Inside Information
Language: English
Company: Siegfried AG
Untere Brühlstrasse 4
4800 Zofingen
Switzerland
Phone: +41 62 746 11 11
E-mail: info@siegfried.ch
Internet: https://www.siegfried.ch
ISIN: CH1429326825
Listed: SIX Swiss Exchange
EQS News ID: 2186524

 
End of Announcement EQS News Service

2186524  21-Aug-2025 CET/CEST

Analysen zu Siegfried Holding AG

  • Alle
  • Kaufen
  • Hold
  • Verkaufen
  • ?
Zu diesem Datensatz liegen uns leider keine Daten vor.
Eintrag hinzufügen

Erfolgreich hinzugefügt!. Zu Portfolio/Watchlist wechseln.

Es ist ein Fehler aufgetreten!

Kein Portfolio vorhanden. Bitte zusätzlich den Namen des neuen Portfolios angeben. Keine Watchlisten vorhanden. Bitte zusätzlich den Namen der neuen Watchlist angeben.

CHF
Hinzufügen

KI Aktien – Gewinner der Digitalisierung – Wall Street Live mit Tim Schäfer

In dieser Folge sprechen wir mit Tim Schäfer live aus New York über den aktuellen Stand der KI-Aktien. Sind die Kurse von Nvidia, Microsoft, Meta, Amazon, Alphabet und Apple noch gerechtfertigt – oder stehen wir kurz vor einer Spekulationsblase?

📈 Tim analysiert die Zahlen, Investitionen und Bewertungen der grossen Tech-Konzerne und zeigt, wie viel Kapital derzeit in KI-Infrastruktur fliesst. Zudem diskutieren wir, welche Randbereiche vom KI-Boom profitieren könnten – etwa Rechenzentren, Stromversorger oder Hardwarehersteller.

Themen im Video:
🔹Die „Magnificent 7“ im Check: Meta, Microsoft, Nvidia, Amazon, Alphabet, Apple
🔹Investitionen in KI: 71 Mrd. bei Meta, 120 Mrd. bei Microsoft
🔹Nvidia: Marktführer, aber extrem teuer
🔹Apple: Aufholjagd oder zu spät dran?
🔹Gefahr einer KI-Blase?
🔹Welche Alternativen bieten sich für Langfristinvestoren?
🔹Rechenzentren, Energieanbieter & Zulieferer im Fokus
🔹Wie Tim mit Rücksetzern und Seitwärtsphasen umgeht
🔹Erste Anzeichen für eine neue Superintelligenz?

👉🏽 https://bxplus.ch/wall-street-live-mit-tim-schaefer/

KI Aktien – Gewinner der Digitalisierung – Wall Street Live mit Tim Schäfer

Mini-Futures auf SMI

Typ Stop-Loss Hebel Symbol
Short 12’873.95 19.48 BWDSCU
Short 13’148.15 13.59 B7ZS2U
Short 13’627.31 8.87 BTASKU
SMI-Kurs: 12’370.57 05.09.2025 17:30:18
Long 11’862.90 19.95 SZNBDU
Long 11’588.73 13.90 BH8SXU
Long 11’079.20 8.90 B38SLU
Die Produktdokumentation, d.h. der Prospekt und das Basisinformationsblatt (BIB), sowie Informationen zu Chancen und Risiken, finden Sie unter: https://keyinvest-ch.ubs.com

finanzen.net News

Datum Titel
{{ARTIKEL.NEWS.HEAD.DATUM | date : "HH:mm" }}
{{ARTIKEL.NEWS.BODY.TITEL}}